Although not mentioned in the quarterly, Layton advised that CP1...

Although not mentioned in the quarterly, Layton advised that CP1 is currently looking into early commercialisation of DermaCann in countries and markets that currently do not have any regulatory requirements. For the US, you must have regulatory approval. In Australia and NZ, you also need approval from relevant bodies. During this time while we await regulatory approval, markets such as South America, South East Asia, and Africa can easily be entered and generate revenue for the company. This can happen now. It is still being discussed and not finalised, hence why I assume it wasn't included in the quarterly.

Micromax microencapsulation technology is also ready for the market now. Looking forward to the market test/commercial trial that is happening Q1 2020.